The Sympathetic Nervous System and Heart Failure

Cardiology Clinics

Volumn 32, Issue 1, 2014, Pages 33-45

  Zhang, David Y ^a   Anderson, Allen S ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Heart failure; Neurohormone; Renin angiotensin aldosterone; Sympathetic nervous system

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTISENSE OLIGONUCLEOTIDE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CELIPROLOL; CLONIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IVABRADINE; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MOXONIDINE; NADOLOL; NEBIVOLOL; PLACEBO; PRAZOSIN; PROPRANOLOL; SPIRONOLACTONE; TIMOLOL; UNINDEXED DRUG;

ADRENERGIC SYSTEM; CHOLINERGIC SYSTEM; CONGESTIVE HEART FAILURE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DRUG MEGADOSE; EXERCISE; FUNCTIONAL STATUS; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART INFARCTION; HEART INNERVATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; KIDNEY DENERVATION; KIDNEY FAILURE; LEFT VENTRICULAR ASSIST DEVICE; LOW DRUG DOSE; MORTALITY; MUSCLE SYMPATHETIC NERVE ACTIVITY; NORADRENALIN RELEASE; NORADRENALIN UPTAKE; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SKELETAL MUSCLE; SLEEP DISORDERED BREATHING; SYMPATHETIC TONE; SYSTOLIC HEART FAILURE;

HEART FAILURE; NEUROHORMONE; RENIN-ANGIOTENSIN-ALDOSTERONE; SYMPATHETIC NERVOUS SYSTEM;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AFFERENT PATHWAYS; ANGIOTENSIN RECEPTOR ANTAGONISTS; AUTONOMIC NERVOUS SYSTEM DISEASES; BRAIN; CARDIAC IMAGING TECHNIQUES; CARDIOTONIC AGENTS; DIGOXIN; EFFERENT PATHWAYS; EXERCISE THERAPY; EXERCISE TOLERANCE; FORECASTING; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; MUSCLE, SKELETAL; MYOCARDIAL INFARCTION; NOREPINEPHRINE; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, BETA; REFLEX; RENIN-ANGIOTENSIN SYSTEM; SLEEP APNEA, OBSTRUCTIVE; SYMPATHETIC NERVOUS SYSTEM;

EID: 84888235756     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2013.09.010     Document Type: Review

References (68)

1. Triposkiadis F., Karayannis G., Giamouzis G., et al. The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. JAm Coll Cardiol 2009, 54(19):1747-1762.
2. Cohn J.N., Pfeffer M.A., Rouleau J., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003, 5(5):659-667.
3. Floras J.S. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. JAm Coll Cardiol 2009, 54(5):375-385.
4. Schwartz P.J. Vagal stimulation for heart diseases: from animals to men. An example of translational cardiology. Circ J 2011, 75(1):20-27.
5. Schwartz P.J., De Ferrari G.M. Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev 2011, 16(2):101-107.
6. Van Stee E.W. Autonomic innervation of the heart. Environ Health Perspect 1978, 26:151-158.
7. Bylund D., Bond R., Clarke D., et al. Adrenoceptors. The IUPHAR compendium of receptor characterization and classification 1998, 58-74. IUPHAR Media, London. Gidlestone (Ed.).
8. Feldman D.S., Elton T.S., Benjmin S., et al. Mechanisms of disease: beta-adrenergic receptors-alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2005, 2(9):475-483.
9. Woodcock E.A., Du X.J., Reichelt M.E., et al. Cardiac alpha 1-adrenergic drive in pathological remodelling. Cardiovasc Res 2008, 77(3):452-462.
10. Al-Hesayen A., Parker J.D. Impaired baroreceptor control of renal sympathetic activity in human chronic heart failure. Circulation 2004, 109(23):2862-2865.
11. Vallbo A.B., Hagbarth K.E., Wallin B.G. Microneurography: how the technique developed and its role in the investigation of the sympathetic nervous system. JAppl Physiol 2004, 96(4):1262-1269.
12. Watson A.M., Hood S.G., May C.N. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol 2006, 33(12):1269-1274.
13. Francis G.S., Goldsmith S.R., Levine T.B., et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984, 101:370-377.
14. Ishise H., Asanoi H., Ishizaka S., et al. Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure. JAppl Physiol 1998, 84(4):1234-1241.
15. Kishi T. Heart failure as an autonomic nervous system dysfunction. JCardiol 2012, 59(2):117-122.
16. Wang H., Parker J.D., Newton G.E., et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. JAm Coll Cardiol 2007, 49(15):1625-1631.
17. Somers V.K., Dyken M.E., Clary M.P., et al. Sympathetic neural mechanisms in obstructive sleep apnea. JClin Invest 1995, 96(4):1897-1904.
18. Spaak J., Eqri Z.J., Kubo T., et al. Muscle sympathetic nerve activity during wakefulness in heart failure patients with and without sleep apnea. Hypertension 2005, 46(6):1327-1332.
19. Usui K., Douglas B.T., Jonas S., et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. JAm Coll Cardiol 2005, 45(12):2008-2011.
20. Graham L.N., Smith P.A., Stoker J.B., et al. Time course of sympathetic neural hyperactivity after uncomplicated acute myocardial infarction. Circulation 2002, 106(7):793-797.
21. Notarius C.F., Spaak J., Morris B.L., et al. Comparison of muscle sympathetic activity in ischemic and nonischemic heart failure. JCard Fail 2007, 13(6):470-475.
22. Middlekauff H.R., Chiu J., Hamilton M.A., et al. Muscle mechanoreceptor sensitivity in heart failure. Am J Physiol Heart Circ Physiol 2004, 287(5):H1937-H1943.
23. Notarius C.F., Atchison D.J., Rongen G.A., et al. Effect of adenosine receptor blockade with caffeine on sympathetic response to handgrip exercise in heart failure. Am J Physiol Heart Circ Physiol 2001, 281(3):H1312-H1318.
24. Rongen G.A., Lambrou G., Smits P., et al. Angiotensin AT1 receptor blockade abolishes the reflex sympathoexcitatory response to adenosine. JClin Invest 1998, 101:769-776.
25. Hausberg M., Kosch M., Harmelink P., et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002, 106(15):1974-1979.
26. Jankowska E.A., Ponikowski P., Piepoli M.F., et al. Autonomic imbalance and immune activation in chronic heart failure-pathophysiological links. Cardiovasc Res 2006, 70(3):434-445.
27. Zucker I.H., Schultz H.D., Patel K.P., et al. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol 2009, 297(5):H1557-H1566.
28. Fisher J.P., Young C.N., Fadel P.J. Central sympathetic overactivity: maladies and mechanisms. Auton Neurosci 2009, 148(1-2):5-15.
29. Huang B.S., Zheng H., Tan J., et al. Regulation of hypothalamic renin-angiotensin system and oxidative stress by aldosterone. Exp Physiol 2011, 96(10):1028-1038.
30. Kang Y.M., Ma Y., Elks C., et al. Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB. Cardiovasc Res 2008, 79(4):671-678.
31. Hirooka Y., Sagara Y., Kishi T., et al. Oxidative stress and central cardiovascular regulation. Pathogenesis of hypertension and therapeutic aspects. Circ J 2010, 74(5):827-835.
32. Garrido A.M., Griendling K.K. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009, 302(2):148-158.
33. Piacentino V., Weber C.R., Chen X., et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003, 92(6):651-658.
34. Dodge-Kafka K.L., Soughaver J., Pare G.C., et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 2005, 437(7058):574-578.
35. Liggett S.B., Tepe N.M., Lorenz J.N., et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000, 101(14):1707-1714.
36. Vasudevan N.T., Mohan M.L., Gupta M.K., et al. Gβγ-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor α-induced cardiac β-adrenergic receptor dysfunction. Circulation 2013, 128(4):377-387.
37. O'Connor C.M., Anand I., Fiuzat M. Additive effects of beta-1 389 Arg/Gly and alpha-2c 322-325 wild-type/del genotype combinations on adjudicated hospitalizations and death in the Beta Blocker Evaluation of Survival Trial (BEST). JCard Fail 2008, 14:S69.
38. O'Connor C.M., Fiuzat M., Carson P.E., et al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One 2012, 7(10):e44324.
39. Fiuzat M., Neely M.L., Starr A.Z., et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-Action DNA substudy. Eur J Heart Fail 2013, 15(3):258-266.
40. Murai H., Takamura M., Kaneko S. Advantage of recording single-unit muscle sympathetic nerve activity in heart failure. Front Physiol 2012, 3:109.
41. 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008, 29(9):1147-1159.
42. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. JNucl Cardiol 2009, 16(1):113-121.
43. Ketchum E.S., Jacobcon A.F., Caldwell J.H., et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. JNucl Cardiol 2012, 19(5):1007-1016.
44. Lopez-Sendon J., Swedberg K., McMurray J., et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004, 25(15):1341-1362.
45. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. NEngl J Med 1996, 334(21):1349-1355.
46. Packer M., Coats A., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. NEngl J Med 2001, 344(22):1651-1658.
47. Failure (MERIT-HF). Lancet 1999, 353(9169):2001-2007.
48. Study II (CIBIS-II): a randomised trial. Lancet 1999, 353(9146):9-13.
49. Beta-Blocker Evaluation of Survival Trial Investigators Atrial of the beta-blocker bucindolol in patients with advanced chronic heart failure. NEngl J Med 2001, 344(22):1659-1667.
50. Poole-Wilson P.A., Swedberg K., Cleland J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362(9377):7-13.
51. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. RESults of a Veterans Administration Cooperative Study. NEngl J Med 1886, 314(24):1547-1552.
52. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEngl J Med 1999, 341(10):709-717.
53. Pitt B., Remme W., Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 2003, 348(14):1309-1321.
54. Thames M.D., Miller B.D., Abboud F.M. Sensitization of vagal cardiopulmonary baroreflex by chronic digoxin. Am J Physiol 1982, 243(5):H815-H818.
55. Ferguson D.W., Berg W.J., Sanders J.S., et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989, 80(1):65-77.
56. Khan M.H., Sinoway L.I. Muscle reflex control of sympathetic nerve activity in heart failure: the role of exercise conditioning. Heart Fail Rev 2000, 5(1):87-100.
57. Zhu G.Q., Gao L., Li Y., et al. AT1 receptor mRNA antisense normalizes enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure. Am J Physiol Heart Circ Physiol 2004, 287(4):H1828-H1835.
58. Kobayashi M., Sakurai S., Takaseva T., et al. Effect of epivascular cardiac autonomic nerve stimulation on cardiac function. Ann Thorac Surg 2012, 94(4):1150-1156.
59. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376(9744):875-885.
60. Esler M.D., Krum H., Schlaich M., et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012, 126(25):2976-2982.
61. DiBona G.F., Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010, 298(2):R245-R253.
62. Krum H., Schlaich M., Whitbourn R., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373(9671):1275-1281.
63. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. NEngl J Med 2006, 355(18):1873-1884.
64. Soppa G.K., Lee J., Staqq M.A., et al. Role and possible mechanisms ofclenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. Cardiovasc Res 2008, 77(4):695-706.
65. Birks E.J., George R.S., Hedqer M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011, 123(4):381-390.
66. Hogg K., McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis 2005, 47(6):357-366.
67. Grassi G., Seravalle G., Quarti-Trevano F., et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension 2009, 53(2):205-209.
68. Markham D.W., Fu Q., Palmer M.D., et al. Sympathetic neural and hemodynamic responses to upright tilt in patients with pulsatile and nonpulsatile left ventricular assist devices. Circ Heart Fail 2013, 6(2):293-299.